Dublin, Aug. 17, 2017 -- The "Deuterated Drugs Formulations Therapeutics Markets Strategies" report has been added to Research and Markets' offering.
Deuterated Drugs: Products, Pipelines, Strategies, Therapeutics and Markets is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug formulation developers, product designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for drugs that incorporate deuterium into the chemical structure of APIs to modify drug properties in vivo. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Deuterated Drugs - What You Will Learn
- What deuterated drugs are currently FDA-approved or in late-stage development, what are their distinguishing properties, how are they marketed, and what are the therapeutic specifics?
- What are the major factors driving the development of deuterated drugs?
- What are the product strategies of deuterated drug developers?
- What is the size of the deuterated drug market today, who are the active sector participants, and what will the market look like in 2024?
- How important are formulator-developer-manufacturer relationships and what are the key alliances in the industry?
- What are the significant economic, technology, and regulatory factors affecting the market for deuterated drugs?
Report Value Matrix
- Managed Care Managers
- Management Consultants
- Financial Analysts
- Pharma Product Managers
- Device Suppliers
- Biotech Managers
- Drug Marketers & Strategists
- Clinical Managers
- Drug Distributors
- Pharma Regulators
- Product Developers
- Component Suppliers
- CMOs, CSOs
Key Topics Covered:
Executive Summary
Drug Therapy Market Dynamics
- Market Segments and Indications
- Competing Technologies
- Market Drivers
- Drug Re-positioning/Re-purposing
- Extending Patent Life
- Dosing Frequency & Patient Adherence
- Competitive Landscape
- Formulators/Developers
- Marketers
- Alliances
- Acquisitions
Deuterated Drug Therapeutics
- Formulation Technology
- Drug Property Kinetics
- Extending Dosing Intervals
- Addressing Unmet Therapeutic Needs
Selected Near-term Therapeutic Targets
- Neurotransmitter Regulation
- Transmembrane Conductance
- Kinase Inhibitors
- Anti-inflammatory
- Mitochondrial Function Modulation
- Antineoplastic
Deuterated Drugs - Near-term Therapeutic Market Analysis
- Addiction
- Autoimmune Diseases
- Hereditary
- Neurology
- Oncology
- Ophthalmology
Market Factors
- Regulations and Approvals
- Clinical Trials & End Points
- IP/Patent Factors
- Defensive Patent Strategies
- Healthcare Economics
Company Profiles
- Alkeus Pharmaceuticals
- Camargo
- Celgene
- CombiPhos
- Concert Pharmaceuticals
- DeuteRx
- Enanta Pharmaceuticals
- Invent Pharmaceuticals
- Lundbeck A/S
- Neuland Laboratories
- Otsuka Pharmaceuticals
- PharmatrophiX
- Protia LLC
- Retrotope
- Teva
For more information about this report visit https://www.researchandmarkets.com/research/q4fsx3/deuterated_drugs
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Instagram Outage Disrupts Thousands of U.S. Users
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



